Haller Michael J, Stein Jennifer, Shuster Jon, Theriaque Douglas, Silverstein Janet, Schatz Desmond A, Earing Michael G, Lerman Amir, Mahmud Farid H
Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL, USA.
Pediatr Diabetes. 2007 Aug;8(4):193-8. doi: 10.1111/j.1399-5448.2007.00246.x.
To assess the ability of reactive hyperemia-peripheral artery tonometry (RH-PAT) to serve as a surrogate marker of endothelial dysfunction in children with type 1 diabetes (T1D).
Forty-four children with T1D [age 14.6 +/- 2.7 yr; duration of diabetes 6.01 +/- 4 yr; range of diabetes duration 1-16 yr; and hemoglobin A1c (HbA1c) 8.34 +/- 1.2%] and 20 children without diabetes (age 14.1 +/- 1.5 yr) underwent RH-PAT endothelial function testing after an overnight fast. Height, weight, body mass index (BMI), blood pressure (BP), fasting lipid profile, and glucose level were determined in each child. Children with T1D underwent a second RH-PAT study 4 wk after their initial study to determine the intrapatient variability of the technique.
Children with T1D had endothelial dysfunction as evidenced by lower mean RH-PAT scores (1.63 +/- 0.5) when compared with children without diabetes (mean RH-PAT score 1.95 +/- 0.3) (p = 0.01). Repeat RH-PAT scores were predicted by initial RH-PAT scores (p = 0.0025). Mean intrapatient standard deviation of RH-PAT score was 0.261 and mean coefficient of variation was 14.8. Variations in RH-PAT score were not explained by differences in glucose, HbA1c, BMI, systolic BP, diastolic BP, or lipids.
Although larger validation studies are required, RH-PAT is a promising non-invasive technique to assess endothelial function in children with T1D. Non-invasive measures of endothelial dysfunction may provide the additional risk stratification data needed to justify more aggressive primary prevention of cardiovascular disease in children with T1D.
评估反应性充血-外周动脉张力测定法(RH-PAT)作为1型糖尿病(T1D)患儿内皮功能障碍替代标志物的能力。
44例T1D患儿[年龄14.6±2.7岁;糖尿病病程6.01±4年;糖尿病病程范围1 - 16年;糖化血红蛋白(HbA1c)8.34±1.2%]和20例非糖尿病患儿(年龄14.1±1.5岁)在空腹过夜后接受RH-PAT内皮功能测试。测定每个患儿的身高、体重、体重指数(BMI)、血压(BP)、空腹血脂谱和血糖水平。T1D患儿在首次研究后4周进行第二次RH-PAT研究,以确定该技术在患者内的变异性。
与非糖尿病患儿相比,T1D患儿存在内皮功能障碍,表现为平均RH-PAT评分较低(1.63±0.5)(非糖尿病患儿平均RH-PAT评分为1.95±0.3)(p = 0.01)。重复RH-PAT评分可由初始RH-PAT评分预测(p = 0.0025)。RH-PAT评分的患者内平均标准差为0.261,平均变异系数为14.8。RH-PAT评分的差异不能用血糖、HbA1c、BMI、收缩压、舒张压或血脂的差异来解释。
尽管需要更大规模的验证研究,但RH-PAT是一种有前景的非侵入性技术,可用于评估T1D患儿的内皮功能。内皮功能障碍的非侵入性测量可能提供额外的风险分层数据,以证明对T1D患儿进行更积极的心血管疾病一级预防是合理的。